文献速递生殖医学

库欣综合征对男性促性腺激素轴及睾丸功能的影响

Impact of Cushing's syndrome on the gonadotrope axis and testicular functions in men.
PubMed 文献 · Hum Reprod · 2023-01-01

该单中心病例对照研究纳入1990年1月至2021年7月诊断的89例男性库欣综合征患者(51例库欣病、29例异位ACTH综合征、9例肾上腺源性),与40名年龄相仿的正常男性比较。结果显示库欣综合征导致不同程度的低促性腺激素性性腺功能减退,异位ACTH综合征患者促性腺激素轴及睾丸功能受损更严重,且多数患者术后可逆转。

要点

  • 库欣综合征男性总睾酮、生物可利用睾酮和游离睾酮均显著低于对照组(P < 0.0001)。
  • 低促性腺激素性性腺功能减退在异位ACTH综合征中占83%,库欣病中占61%,肾上腺源性中占33%。
  • 成功治疗后平均6.0 ± 4.3年,75%的性腺功能减退患者逆转。

核心结论

  • 内源性皮质醇增多导致男性不同程度的低促性腺激素性性腺功能减退,其严重程度与高皮质醇血症强度及病因相关。
  • 异位ACTH综合征患者促性腺激素轴及睾丸功能受损更严重,并伴有生精异常。
  • 多数患者库欣综合征缓解后性腺功能减退可逆转。

研究设计与样本

  • 单中心病例对照研究,纳入1990年1月至2021年7月于巴黎萨克莱大学Bicêtre医院诊断的89例男性库欣综合征患者,与40名年龄相仿的正常男性对照。
  • 患者组包括51例库欣病、29例异位ACTH综合征和9例肾上腺源性库欣综合征(ACTH非依赖性)。
  • 所有患者均有明显高皮质醇血症,两次独立样本24小时尿游离皮质醇升高。
  • 对20例有缓解后数据的患者进行纵向分析以评估促性腺激素轴及睾丸功能缺陷的可逆性。

主要发现

  • 与对照组相比,库欣综合征男性总睾酮、生物可利用睾酮和游离睾酮均显著降低(P < 0.0001)。
  • 低促性腺激素性性腺功能减退(血清总睾酮<3.0 ng/ml)在异位ACTH综合征中占83%,库欣病中占61%,肾上腺源性中占33%。
  • 库欣病患者血清性激素结合球蛋白水平较对照组中度降低(P = 0.01)。
  • 异位ACTH综合征患者总睾酮、LH和FSH水平显著低于库欣病或肾上腺源性患者,且为唯一血清FSH(P = 0.002)、抑制素B(P < 0.0001)和抗苗勒管激素(P = 0.003)均显著降低的组。
  • 库欣病患者血清INSL3水平显著低于对照组(P = 0.03);24小时尿游离皮质醇和ACTH与多数生殖激素(包括LH、FSH、总睾酮和抑制素B)呈显著负相关。

临床怎么用

  • 作者认为,本研究结果揭示了库欣综合征男性生殖功能受损的谱系,其损伤程度取决于高皮质醇血症强度及相关病因。
  • 作者认为,高皮质醇血症与促性腺激素轴及睾丸功能受损的因果联系由多数患者缓解后的可逆性所证实。
  • 作者认为,本发现可能推广至更常见的医源性库欣综合征,即因长期接触外源性糖皮质激素所致。

局限性

  • 回顾性设计可能带来的偏倚被迄今最大男性库欣综合征队列的分析以及严格的纳入和排除标准所抵消。
  • 由于本研究中接受精液分析的患者数量少,需要进一步研究以揭示库欣综合征男性生精缺陷的全貌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does Cushing's syndrome (CS) differently affect the gonadotrope axis and testicular functions (GA/TF) according to the hypercortisolism intensity and underlying etiology? SUMMARY ANSWER: Endogenous cortisol excess caused by CS leads to varying degrees of hypogonadotropic hypogonadism (HH) with more severe GA/TF impairment and altered spermatogenesis in men with intense hypercortisolism associated with paraneoplastic/ectopic adrenocorticotrophic hormone (ACTH) secretion (EAS). WHAT IS KNOWN ALREADY: CS is very rarely studied in men due to its lower prevalence in men than in women. In a few old reports focusing exclusively on a limited number of men with Cushing's disease (CD), the occurrence of hypogonadism was reported. However, a detailed assessment of the impact of CS on the GA/TF in a significant series of patients has not been performed. Yet, hypogonadism could worsen CS-associated comorbidities such as osteoporosis and myopathy. To date, the full spectrum of GA/TF impairment in men with CS of different etiologies and intensity remains unknown. STUDY DESIGN, SIZE, DURATION: In this monocentric study, 89 men with CS diagnosed at a tertiary endocrine university center (Bicêtre, Paris Saclay) between January 1990 and July 2021 were evaluated and compared to 40 normal men of similar age. PARTICIPANTS/MATERIALS, SETTING, METHODS: The CS patient cohort of 89 men included 51 with CD, 29 with EAS and 9 with CS of adrenal origin i.e. (ACTH-independent CS (AI-CS)). They all had frank hypercortisolism, with increased 24 h-urinary-free cortisol (24 h-UFC) in two separate samples. A case-control study was performed focusing on pituitary gonadotrope function and testicular sex steroids and peptides. An additional set of six CS men had an evaluation including semen analysis. In a subgroup of 20 men with available data after CS remission, a longitudinal analysis was conducted to assess the reversibility of GA/TF defects. MAIN RESULTS AND THE ROLE OF CHANCE: Compared to controls, men with CS had significantly lower total testosterone (TT), bioavailable TT, and free TT (P < 0.0001). Hypogonadism, defined as serum TT levels <3.0 ng/ml, was present in 83% of men with EAS, in 61% of men with CD, and in 33% of men with AI-CS. Low-normal LH concentrations in the included men with hypercortisolism indicated HH. Serum sex hormone-binding globulin levels were moderately decreased in men with CD (P = 0.01 vs controls). Among the CS men, those with EAS had significantly lower TT, LH, and FSH levels than those with CD or AI-CS. When compared to controls, patients with EAS were the only group exhibiting a significant decrease in both serum FSH (P = 0.002) and the testicular peptides inhibin B (P < 0.0001) and anti-Müllerian hormone (P = 0.003). Serum INSL3 levels were significantly lower in men with CD than in the controls (P = 0.03). Of note, 24 h-UFC and ACTH were inversely and significantly associated with the majority of reproductive hormones including LH, FSH, TT, and inhibin B. Following successful curative therapy, reproductive assessment at a mean of 6.0 ± 4.3 years showed a significant increase in serum TT (P < 0.0001) and plasma LH (P = 0.02) levels, indicating a reversal of HH in 75% of the affected males. Among the six patients with available semen analysis, the two EAS cases exhibited a decrease in Sertoli cell peptides associated with a severe oligozoospermia, which completely normalized following removal of the source of hypercortisolism. LIMITATIONS, REASONS FOR CAUTION: The potential bias due to the retrospective design is counteracted by the analysis of the largest male CS cohort to date as well as the use of stringent inclusion and exclusion criteria. Due to the low number of patients with semen analysis in this study, further research is needed to unravel the full spectrum of spermatogenesis defects in men with CS. WIDER IMPLICATIONS OF THE FINDINGS: This work reveals the variable spectrum of reproductive impact in men with CS. We demonstrate that GA/TF impairment depends on the intensity of hypercortisolism which in turn is related to the underlying etiology. The causal link between hypercortisolism and GA/TF impairment was attested by its reversibility in most patients after CS remission. The wider implications of our findings lie in the potential generalization to a much commoner entity, iatrogenic CS due to chronic exposure to exogenous glucocorticoids. STUDY FUNDING/COMPETING INTEREST(S): Several research grants were attributed to J.Y.: (i) a grant from Programme Hospitalier de Recherche Clinique (PHRC # P081212 HYPOPROTEO); (ii) a grant from the French Association of Patients with Adrenal Diseases ('Association surrénales'); and (iii) independent Investigator Research Grants from HRA Pharma, Novartis and Recordati Pharma. A SICPA Foundation grant (Lausanne, Switzerland) allowed protected research time for G.E.P. The above sponsors were not involved in any part of the study. The authors have no competing or other conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Papadakis GE, de Kalbermatten B, Dormoy A, et al. Impact of Cushing's syndrome on the gonadotrope axis and testicular functions in men. Hum Reprod. 2023. PMID: 37742130. doi:10.1093/humrep/dead187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。